氟达拉滨治疗慢性淋巴细胞白血病临床研究  

Clinical Study on Efficiency of Fludarabine-based Regimen for the Patients with Chronic Lymphocytic Leukemia

作　　者：王卫敏[1] 孙慧[1] 谢新生[1] 甘思林[1] 马平[1] 

机构地区：[1]郑州大学第一附属医院血液科,河南郑州450052

出　　处：《中国实验血液学杂志》2012年第1期70-72,共3页Journal of Experimental Hematology

摘　　要：本研究观察氟达拉滨治疗慢性淋巴细胞白血病(CLL)的疗效及其不良反应。2004年4月至2011年4月在郑州大学第一附属医院收治的40例CLL患者,分为单药应用氟达拉滨(F)组和氟达拉滨联合环磷酰胺(FC)组。F组18例,氟达拉滨30 mg/(m2.d),连用3 d,28 d为1个周期;FC组22例,氟达拉滨25 mg/(m2.d),环磷酰胺250 mg/(m2.d),连用3 d,28 d为1个周期。结果表明,40例患者完全缓解(CR)16例(40.0%)、部分缓解(PR)20例(50.0%)、总反应率(OR)90.0%。F组CR 3例(16.7%)、PR 11例(61.1%)、OR 14例(77.8%)。FC组CR 13例(59.1%)、PR 9例(40.9%)、OR 22例(100%)。与F组比较,FC组CR率、OR率均有提高(P<0.05)。不良反应主要为骨髓抑制和免疫功能抑制,F组与FC组比较,粒细胞减少及血小板减少发生率增多,但严重感染发生率并未增多。结论:氟达拉滨治疗CLL的CR率、OR率高。与单用氟达拉滨相比,氟达拉滨与环磷酰胺伍用方案进一步提高了CR率,不良反应无显著增加。氟达拉滨与环磷酰胺伍用方案是治疗CLL的安全有效的一线方案。The aim of this study was to evaluate the therapeutic effects and adverse reactions of fludarabine-based regimen for patients with chronic lymphocytic leukemia （CLL）. 18 patients with CLL were treated with F regimen [ fludarabine 30 rag/（ m2·d） intravenously for 3 d, repeatedly every 28 days 3. 22 patients were treated with FC regimen · fludarabine 25 mg/（m2 ~ d） plus cyclophosphamide 250 mg/（m2 · d） intravenously for 3 d, repeatedly every 28 days）. The results showed that the rate of complete remission （CR）, partial remission （PR） and overall remission （OR） reached 16.7%, 61.1% and 77.8% in the F regimen groups and 59.1% ,40.9% and 100% in the FC regimen groups （ P 〈 0.05, P 〉 0.05 and P 〉 0.05 ）, respectively. FC regimen resulted in significantly higher CR rate than that in single-agent fludarabine regimen. The main adverse reactions were myelosuppression and immunosuppression. No significiant differences were found between the two regimens. FC regimen did not increase the rate of severe infections. It is concluded that FC regimen can give higher CR rate as compared with F regimen, fludarabine-based regimens is effective and safe first-line regimen for patients with CLL.

关 键 词：氟达拉滨 环磷酰胺 慢性淋巴细胞白血病 

分 类 号：R733.72[医药卫生—肿瘤]